Terns Pharmaceuticals – 2025-11-18 - Increase Confidence 7/10

TERN – increase in Days/Weeks

Terns Pharmaceuticals reported a deepening net loss of $21.9 million in Q3 2024, reflecting ongoing negative free cash flow typical of clinical-stage biotechs. However, the company’s cash runway now extends into 2028 following a $172.7 million equity raise, with critical interim Phase 1 data for its CML drug TERN-701 expected in early December 2024.

Why This Matters

The combination of extended financial runway and proximity to a high-impact clinical readout fundamentally shifts investor risk perception: while the company remains unprofitable and cash-burning, the near-zero probability of near-term dilution removes a key overhang, allowing the market to focus purely on the value of upcoming data. With TERN-701’s interim results due in early December—just days away—the stock is positioned for a potential catalyst-driven rally, especially given the high unmet need in resistant CML and the drug’s novel allosteric mechanism.

Key Insights

• Cash Runway: $372.8 million in cash, equivalents, and marketable securities → funding secured into 2028
• News Impact: Interim Phase 1 data for TERN-701 (CML) expected early December 2024 → major binary catalyst
• Risk/Offset: Clinical failure or safety concerns in TERN-701 could trigger sharp downside; obesity programs remain earlier-stage

Practical Implications

• Bull Case: Positive TERN-701 interim data (safety + early efficacy) → 20–30% upside in days
• Bear Case: Adverse safety signals or weak efficacy → 30%+ drop on risk-off sentiment
• Confidence: 7/10 – High-visibility catalyst imminent, balance sheet de-risks near-term funding fears

Prediction: increase

Reference:

• https://seekingalpha.com/pr/19913489-terns-pharmaceuticals-reports-third-quarter-2024-financial-results-and-corporate-updates